HOOKIPA PharmaHOOK 49 Quick Ratio is 3.93 as of Jun. 2025, which is 12% below its 10-year median of 4.48. GuruFocus rates HOOK with a GF Score™ of 49/100 and a GF Value™ of $2.78 (Possible Value Trap). The stock has 6 warning signs investors should review. Among 1,417 Biotechnology companies, HOOKIPA Pharma ranks better than 52.51% on this metric.
The quick ratio measures a company's ability to meet its short-term obligations with its most liquid assets. It is calculated as a company's Total Current Assets excludes Total Inventories divides by its Total Current Liabilities. HOOKIPA Pharma's quick ratio for the quarter that ended in Jun. 2025 was 3.93.
HOOKIPA Pharma has a quick ratio of 3.93. It generally indicates good short-term financial strength.
The historical rank and industry rank for HOOKIPA Pharma's Quick Ratio or its related term are showing as below:
HOOK'
s Quick Ratio Range Over the Past 10 Years
Min: 3.16 Med: 4.48 Max: 17.34
Current: 3.93
During the past 8 years, HOOKIPA Pharma's highest Quick Ratio was 17.34. The lowest was 3.16. And the median was 4.48.
HOOK's Quick Ratio is ranked better than 52.51% of 1417
companies
in the Biotechnology industry
Industry Median: 3.6
vs HOOK: 3.93
HOOKIPA Pharma (OTCPK:HOOK) Quick Ratio Explanation
The quick ratio is more conservative than the Current Ratio because it excludes inventories from current assets. The ratio derives its name presumably from the fact that assets such as cash and marketable securities are quick sources of cash. Inventories generally take time to be converted into cash, and if they have to be sold quickly, the company may have to accept a lower price than book value of these inventories. As a result, they are justifiably excluded from assets that are ready sources of immediate cash.
In general, low or decreasing quick ratios generally suggest that a company is over-leveraged, struggling to maintain or grow sales, paying bills too quickly or collecting receivables too slowly. On the other hand, a high or increasing quick ratio generally indicates that a company is experiencing solid top-line growth, quickly converting receivables into cash, and easily able to cover its financial obligations. Such companies often have faster inventory turnover and cash conversion cycles.
The higher the quick ratio, the better the company's liquidity position.
HOOKIPA Pharma Quick Ratio Related Terms
HOOKIPA Pharma Quick Ratio Historical Data
* Premium members only.
The historical data trend for HOOKIPA Pharma's Quick Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, HOOKIPA Pharma's Quick Ratio, along with its competitors' market caps and Quick Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
HOOKIPA Pharma Quick Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, HOOKIPA Pharma's Quick Ratio distribution charts can be found below:
* The bar in red indicates where HOOKIPA Pharma's Quick Ratio falls into.
The quick ratio measures a company's ability to meet its short-term obligations with its most liquid assets. For this reason, the ratio excludes inventories from current assets.
HOOKIPA Pharma's Quick Ratio for the fiscal year that ended in Dec. 2024 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
HOOKIPA Pharma (HOOK) has a Quick Ratio of 3.93 as of Jun. 2025. Quick ratio is the ratio of current assets less inventory to current liabilities. View historical data on HOOKIPA Pharma and its competitors. This is 12% below median its historical median of 4.48. Over the past decade, HOOKIPA Pharma's Quick Ratio has ranged from 3.16 to 17.34. According to the industry distribution chart, HOOKIPA Pharma ranks #673 out of 1417 companies in the Biotechnology industry, placing it in the top 47.5%.
Is HOOKIPA Pharma's Quick Ratio too high?
HOOKIPA Pharma's current Quick Ratio of 3.93 is 12% below median its 10-year median of 4.48. Over the past 10 years, this metric has ranged from a low of 3.16 to a high of 17.34. The Biotechnology industry median Quick Ratio is 3.60. HOOKIPA Pharma's value of 3.93 is 9.2% above this industry median. Based on the distribution chart, HOOKIPA Pharma ranks #673 out of 1417 companies in the Biotechnology industry, which is above the industry midpoint. Overall, HOOKIPA Pharma has a GF Score™ of 49/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does HOOKIPA Pharma's Quick Ratio compare to LNAI and ZEOX?
According to the Biotechnology industry distribution chart, HOOKIPA Pharma ranks #673 out of 1417 companies for Quick Ratio. This puts HOOKIPA Pharma in the upper half of its industry. The industry median Quick Ratio is 3.60. HOOKIPA Pharma's value of 3.93 is 9.2% above this benchmark. Historically, HOOKIPA Pharma's own Quick Ratio has ranged from 3.16 to 17.34 over the past decade. While the company's 10-year median is 4.48 vs. the industry median of 3.60, HOOKIPA Pharma has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Quick Ratio for a Biotechnology company?
The median Quick Ratio among Biotechnology companies is 3.60, based on 1,417 companies in the industry. Companies in the top quartile (top 25%) have a Quick Ratio significantly above this median, while those in the bottom quartile fall well below. However, Quick Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. HOOKIPA Pharma's current Quick Ratio of 3.93 is 9.2% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Quick Ratio mean?
A high Quick Ratio can signal that a stock is expensive relative to its fundamentals. Quick ratio is the ratio of current assets less inventory to current liabilities. View historical data on HOOKIPA Pharma and its competitors. For the Biotechnology industry, the median Quick Ratio is 3.60 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. HOOKIPA Pharma's current Quick Ratio is 3.93, which is 12% below median its own 10-year median of 4.48. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is HOOKIPA Pharma stock overvalued right now?
Based on GuruFocus' analysis, HOOKIPA Pharma (HOOK) is currently considered Possible Value Trap. The stock's GF Value™ is $2.78, compared to a current price of $1.15 — trading 58.6% below its estimated fair value. The current Quick Ratio is 3.93, which is 12% below median its 10-year median of 4.48 and 9.2% above the Biotechnology industry median of 3.60. HOOKIPA Pharma's overall GF Score™ is 49/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Quick Ratio calculated?
Quick Ratio is calculated from a company's financial statements. For HOOKIPA Pharma (HOOK), the current Quick Ratio is 3.93 as of Jun. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is HOOKIPA Pharma (HOOK) Overvalued in 2026?
Based on GuruFocus' analysis, HOOKIPA Pharma stock appears to be undervalued.
The current stock price of $1.15 is trading 58.6% below its estimated GF Value™ of $2.78.
GuruFocus considers HOOKIPA Pharma to be Possible Value Trap.
Key valuation signals for HOOK:
Quick Ratio: 3.93 (12% below median its 10-year median of 4.48)
GF Value™: $2.78 vs. price of $1.15 (58.6% below fair value)
Industry Position: 9.2% above the Biotechnology median (#673 of 1417)
No single metric tells the full story. See the HOOK stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
HOOKIPA Pharma Inc is a clinical-stage biopharmaceutical company developing a class of immunotherapeutics targeting infectious diseases and cancers based on its proprietary arenavirus platform that is designed to reprogram the body's immune system. The company's product candidates are designed to induce specific, robust and durable CD8+ T cells and antibodies to eliminate cancers and serious infectious diseases. Its pipeline includes biological therapies for oncology, targeting human papillomavirus type 16-positive (HPV16+) cancers, KRAS mutated cancers, and other targets. In addition, It is also focused to develop therapies that are intended to provide functional cures for hepatitis B virus (HBV) and human immunodeficiency virus-1 (HIV-1).
49GF Score
Get the complete analysis for HOOK
Quick Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HOOK has been successfully added to your 
